Encompass Health (NYSE:EHC – Get Rating) had its price target lowered by investment analysts at Credit Suisse Group from $63.00 to $62.00 in a research note issued to investors on Wednesday, MarketBeat reports. The firm presently has an "outperform" rating on the stock. Credit Suisse Group's target price would indicate a potential upside of 28.98% from the company's previous close.

Other research analysts have also issued reports about the company. Royal Bank of Canada dropped their price target on Encompass Health from $82.00 to $66.00 in a research report on Wednesday, August 24th. Truist Financial dropped their target price on Encompass Health from $75.00 to $65.00 and set a "buy" rating on the stock in a research report on Monday, August 8th. BMO Capital Markets dropped their target price on Encompass Health from $83.00 to $65.00 and set an "outperform" rating on the stock in a research report on Thursday, August 4th. Barclays dropped their target price on Encompass Health from $80.00 to $63.00 and set an "overweight" rating on the stock in a research report on Thursday, August 4th. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on Encompass Health from $80.00 to $62.00 in a research report on Wednesday, August 3rd. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $70.00.

Encompass Health Stock Down 1.6 %

NYSE:EHC opened at $48.07 on Wednesday. The firm has a market capitalization of $4.80 billion, a price-to-earnings ratio of 14.70, a PEG ratio of 2.37 and a beta of 1.02. Encompass Health has a 1-year low of $44.33 and a 1-year high of $78.31. The company has a current ratio of 1.24, a quick ratio of 1.24 and a debt-to-equity ratio of 1.29. The business's fifty day moving average price is $50.78 and its 200 day moving average price is $59.17.

Insider Activity

In related news, CEO Mark J. Tarr sold 20,449 shares of the stock in a transaction that occurred on Wednesday, August 17th. The stock was sold at an average price of $53.25, for a total transaction of $1,088,909.25. Following the completion of the sale, the chief executive officer now owns 440,895 shares in the company, valued at approximately $23,477,658.75. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 2.70% of the stock is currently owned by insiders.

Institutional Trading of Encompass Health

Several hedge funds have recently added to or reduced their stakes in EHC. Baupost Group LLC MA boosted its stake in Encompass Health by 318.9% during the 1st quarter. Baupost Group LLC MA now owns 3,000,000 shares of the company's stock valued at $213,330,000 after purchasing an additional 2,283,900 shares during the period. Empyrean Capital Partners LP bought a new stake in Encompass Health during the 1st quarter valued at approximately $81,506,000. Massachusetts Financial Services Co. MA lifted its position in shares of Encompass Health by 88.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 1,685,880 shares of the company's stock worth $94,494,000 after acquiring an additional 792,813 shares during the period. Paradice Investment Management LLC bought a new stake in shares of Encompass Health in the 1st quarter worth approximately $47,388,000. Finally, Victory Capital Management Inc. lifted its position in shares of Encompass Health by 40.0% in the 2nd quarter. Victory Capital Management Inc. now owns 2,146,910 shares of the company's stock worth $120,335,000 after acquiring an additional 613,547 shares during the period. Institutional investors own 93.07% of the company's stock.

Encompass Health Company Profile

(Get Rating)

Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.

Featured Stories

• Get a free copy of the StockNews.com research report on Encompass Health (EHC)
• What Steelcase's Earnings Say About the Return to the Office?
• The Institutions Hold On To Darden Restaurants International
• Is The Golden Age Of Homebuilding Already Over?
• These 3 Big Dividend Payers Also Boast Strong Price Growth
• Natural Gas Prices Continue To Rally, These Stocks Should Benefit

Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.